The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Grisly tales are emerging from the corridors of the US Food & Drug Administration (FDA) as mass sackings  take effect.

After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

LifeMine restructures with layoffs; PTC's Translarna is pulled in Europe; Opthea ends AMD trials; Apollomics and LaunXP make ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

Shares of Opthea Limited (NASDAQ:OPT – Get Free Report) have been assigned an average recommendation of “Hold” from the six ...